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Abstract 
Introduction: Acute postoperative pain results from a surgical procedure. 
Despite the improvements in the physiopathology and management of postoperative 
pain, we still don’t provide acceptable levels of care. To allow a greater efficacy in 
treating pain with fewer secondary effects, old drugs have been revived. Among these, 
gabapentinoids, tricyclic anti-depressants and ketamine can reduce central sensitization 
and thus decrease pain. This review focuses on their use in acute postoperative pain 
management. 
Methods: Data were compiled from previous systematic reviews and meta-
analyses published from 2007 to 2016 in MEDLINE. The three outcomes investigated 
were postoperative pain, opioid consumption and opioid-related side effects. All 
outcomes were analysed at 24h postoperative and up to 72h after surgery, if data were 
available. 
Results: The effect of gabapentinoids and ketamine seems to be greater on the 
reduction of opioid consumption than on postoperative pain as there was a more 
homogeneous reduction in opioid requirements. Results are even more inconsistent 
regarding opioid side effects but the overall trend favours a reduction by both 
gabapentinoids and ketamine. The best analgesic dose is yet to be discovered. However, 
effective gabapentin doses ranged from 300mg/d to 1200mg/d; pregabalin doses inferior 
to 100mg/d had little effect; ketamine was always used in sub-anaesthetic doses, i.e. no 
more than 1.0mg/Kg when given as an I.V. bolus and no greater than 1.2mg/Kg/h when 
given as an infusion (either I.V. or epidurally). Regarding tricyclic anti-depressants, the 
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results are mixed but are also of reduced clinical significance given the low number of 
studies available. 
Discussion and Conclusion: This uneven results can be explained by variations 
in anaesthetic protocols (with or without regional analgesia), analgesic regimens 
(different type, number and dosage of drugs, PCA protocols) and hospital practices 
(drugs prescription and administration, pain assessment and registering). The reduction 
in side effects may be due to the drugs themselves but may also be a consequence of the 
decreased opioid consumption. These drugs, particularly gabapentinoids and ketamine, 
appear to be more effective in more painful surgeries that involve peripheral nerve 
injury, causing neuropathic postoperative pain and requiring higher opioid doses. Their 
use was associated with minor side effects, namely sedation, dizziness and 
hallucinations, limited to a short time after surgery. Future research is needed and 
should focus on dose-response and cost-efficacy analysis, using similar anaesthetic 
protocols and populations. 
 
Resumo 
Introdução: A dor aguda pós-operatória resulta de um procedimento cirúrgico. 
Apesar de grandes avanços na sua fisiopatologia, ainda existem falhas no seu 
tratamento. Para obter uma maior eficácia com menos efeitos secundários, velhos 
fármacos foram ressuscitados. Entre estes, os gabapentinóides, os antidepressivos 
tricíclicos e a ketamina podem reduzir a sensibilização central e, assim, diminuir a dor. 
Esta revisão centra-se no uso dos fármacos mencionados no tratamento da dor aguda 
pós-operatória. 
Métodos: Os dados foram obtidos a partir de revisões sistemáticas e meta-
análises publicadas de 2007 a 2016 na MEDLINE. Os três outcomes avaliados foram a 
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dor pós-operatória, o consumo de opioides e os efeitos secundários relacionados com os 
opioides. Todos foram analisados às 24h pós-operatórias e até às 72h após a cirurgia, 
caso houvesse dados disponíveis. 
Resultados: O efeito dos gabapentinóides e da ketamina aparenta ser maior na 
redução do consumo de opioides do que na dor pós-operatória, ocorrendo uma 
diminuição mais homogénea nas necessidades de opioides. Os resultados são ainda mais 
inconsistentes em relação aos efeitos secundários dos opióides, mas parecem favorecer 
uma redução, tanto pelos gabapentinóides como pela ketamina. A dose analgésica ideal 
está ainda por determinar. No entanto, doses eficazes de gabapentina variaram entre 
300mg/d e 1200mg/d; pregabalina não teve efeito se inferior a 100mg/d; ketamina foi 
utilizada em doses sub-anestésicas, ou seja, bolus I.V. não superiores 1.0mg/Kg e uma 
taxa de infusão (I.V. ou epidural) não superior a 1.2mg/Kg/h. Relativamente aos 
antidepressivos tricíclicos, os resultados são contraditórios, mas, dado o reduzido 
número de estudos, têm diminuto valor. 
Discussão e Conclusões: Estes resultados inconsistentes podem ser explicados 
por variações nos protocolos anestésicos (uso ou não de analgesia regional), regimes 
analgésicos (diferente tipo, número e dosagem de fármacos e protocolos de PCA) e nas 
práticas hospitalares (prescrição e administração de fármacos, avaliação e registo da 
dor). A redução dos efeitos secundários pode resultar dos próprios fármacos, ou ser 
consequência da diminuição do consumo de opioides. Os fármacos avaliados, sobretudo 
os gabapentinóides e a ketamina, aparentam ser mais eficazes em cirurgias mais 
dolorosas, que envolvam lesão nervosa periférica, a qual está na origem de dor pós-
operatória neuropática e de maior consumo de opióides. O seu uso foi associado a 
efeitos secundários menores, nomeadamente, sedação, tonturas e alucinações, limitados 
a um curto período de tempo após a cirurgia. É necessária mais investigação, que se 
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deve focar em estudos de dose-resposta e análises custo-benefício, utilizando protocolos 
anestésicos e populações semelhantes. 
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1. Introduction 
 
Acute postoperative pain results from a surgical procedure.1 It is mediated at the 
central (CNS) and peripheral nervous systems via multiple somatic and visceral pain 
mechanisms and pathways.2, 3 
Postoperative pain has nociceptive and neuropathic components. The first is 
responsible for painful impulses conduction and perception in the CNS. The second 
results from nerve fibre damage that modifies pain modulation and leads to central 
sensitization. No effective treatment exists to reduce this mechanism.2, 3 
Several aspects predict the intensity of post-operative pain and analgesic needs, 
such as surgery type, patient’s age, gender, pre-existing pain, anxiety and pain 
catastrophizing.2 The type of surgery is particularly important, with major thoracic, 
abdominal and orthopaedic surgeries associated with intense prolonged postoperative 
pain.2, 4 
Postoperative pain has a negative impact from its cardiovascular, respiratory, 
gastrointestinal and metabolic complications, which result in high morbidity and 
mortality. Activation of sympathetic and neuroendocrine systems can lead to 
tachycardia, hypertension, hyperglycaemia, immunosuppression, decreased regional 
blood flow, venous stasis, and platelet aggregation.2, 3 It can also greatly impair patient 
rehabilitation by reducing mobilization, increasing length of stay, hospital readmission, 
and the risk of persistent postoperative pain, decreasing overall quality of life.4, 5 
Despite the improvements in the physiopathology and management of 
postoperative pain, we are still failing in providing patients acceptable levels of care. It 
is estimated that more than 80% of surgical patients suffer from acute postoperative 
pain,5 65% experience moderate pain and 40% severe pain, respectively.2 If we take into 
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account the introduction of new standards, techniques, guidelines, and educational 
efforts in the last decades, it is not acceptable that only one in four patients has an 
appropriate pain prescription in the postoperative period.2 Causes for poor postoperative 
pain control are multifactorial, including the scarceness and difficulty in pain 
assessment and documentation, deficiencies in pain education for health-care workers, 
patients and their families, lack of adherence to existing guidelines and protocols and 
underuse of effective analgesic techniques.2, 3 
In most cases, multimodal analgesia, including opioid and non-opioid 
combinations, with or without local anaesthetics, is used to treat postoperative pain.1-3 
These type of analgesic schemes didn’t prove 100% effective in eliminating 
postoperative pain and were often associated with a variety of undesirable side effects.  
The number of drugs and techniques available to treat pain is very large and is 
growing every day. Currently, the multimodal analgesic regimens include not only new 
analgesic tools but have revived older ones to allow a greater efficacy in treating pain 
with fewer secondary effects. Among these older tools, gabapentinoids, tricyclic anti-
depressants and N-methyl-D-aspartate receptor antagonists have gain a place of 
significance, as they can decrease pain and chronification by reducing central 
sensitization. 
This review focuses on the role of such drugs in acute postoperative pain 
management. 
 
2. Methods 
 
Data were compiled from previous systematic reviews and meta-analyses 
searched on MEDLINE. The following MeSH search terms were used: “Pain, 
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Postoperative”, “Gabapentin”, “Pregabalin”, “Antidepressive Agents” and “Ketamine”. 
The last search was performed on the 31st December 2016. 
Studies meeting inclusion criteria were identified by title and abstract. Inclusion 
criteria were the following: reviews, systematic reviews and meta-analyses written in 
English and published from 2007 to 2016 and concerning adults only, i.e. older than 18 
years of age. The number of patients included ranged from a minimum of 220 to a 
maximum of 9800. 
The three main outcomes investigated in this review were postoperative pain, 
directly measured on different pain assessment scales (VAS - visual analogic scale, 
NRS – numeric range scale, VRS – verbal range scale, etc.), total postoperative opioid 
consumption and opioid-related side effects (PONV – postoperative nausea and 
vomiting). The side effects related to the use of this drugs were also assessed. All 
outcomes were analysed at 24h postoperative and up to 72h after surgery, if data were 
available.  
Results regarding the three outcomes were then divided into four major surgical 
categories: cardiothoracic, abdominal (either classic or laparoscopic), gynaecological 
(either classic or laparoscopic) and orthopaedic surgeries. 
 
3. Results 
 
3.1 Gabapentinoids 
 
Gabapentinoids were first developed as membrane stabilizing anticonvulsants 
and are also currently used in the treatment of neuropathic pain.6, 7 Despite their name, 
gabapentinoids do not bind to the gamma aminobutyric acid (GABA) receptors, 
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GABAA or GABAB, do not block GABA uptake or metabolism nor have any direct 
GABAergic effect.7, 8  
Gabapentin and pregabalin share a specific high-affinity binding site on the α2δ-
subunit of presynaptic N-type voltage-gated calcium channels distributed throughout the 
central and peripheral nervous systems.6-9 Binding of gabapentinoids to the calcium 
channel decreases the depolarization-induced influx of calcium and reduces the release 
of numerous neurotransmitters, namely, glutamate, aspartate, substance P, calcitonin-
gene-related peptide, dopamine, serotonin and noradrenaline.6-11 Up-regulation of the 
α2δ-subunit in dorsal root ganglions and spinal cord neurons plays a major role in the 
central sensitization following tissue injury and inflammation. Gabapentinoids may 
modulate postoperative pain by decreasing the hyperexcitability of dorsal horn neurons 
thus reducing hyperalgesia and central sensitization, especially in surgeries in which 
nerve injury may occur.7-9, 12-16 
Gabapentin is absorbed in the small intestine by a combination of diffusion and 
facilitated transport via a saturable L-amino acid transport system and its bioavailability 
is inversely dependent on the dose,6-8, 11 being also decreased by 20% with concurrent 
antacid use up to 2h after gabapentin administration.7, 8, 11, 16 Pregabalin, however, has a 
more favourable linear pharmacokinetic profile. Its absorption is extensive and rapid, its 
bioavailability is 90 %, independent of dose, and its binding affinity for the α2δ-subunit 
is six times more potent than that of gabapentin.6, 7, 9, 10, 12, 13, 17 Unlike other 
anticonvulsant drugs, gabapentinoids are not metabolized in the liver nor do they 
interfere with hepatic microsomal enzymes, being eliminated unchanged in the urine. 
Thus, renal impairment decreases their excretion in a linear fashion with creatinine 
clearance. The elimination half-life of gabapentin is between 5 and 9 hours7, 8, 11 and 
pregabalin’s is around 6.5h.7, 9 Both gabapentinoids are available as oral solutions only. 
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Gabapentinoids are well tolerated. The most common side effects are 
somnolence and dizziness, but headaches, blurred vision, ataxia, confusion, peripheral 
oedema and weight gain have also been described, especially after long-lasting use.7-9, 
11, 16-18 
 
3.1.1 Gabapentin 
 
Several reviews and meta-analyses assessed the effect of oral gabapentin in 
postoperative pain, opioid consumption and/or opioid-related side effects, using various 
therapeutic regimens, regardless of the type of surgical procedure. Most studies 
conclude that preoperative administration of gabapentin reduces all three outcomes, 
while some of them report an increase in patient sedation and dizziness but a decreased 
anxiety. No agreement has yet been reached as to which dose provides the best 
analgesia but there seems to be an understanding that for doses higher than 1200mg/d 
the risk of side effects is too high and for doses lower than 300mg/d the effects are 
irrelevant.8, 11, 17, 19-21 
In most studies, gabapentin is used as part of a balanced analgesic scheme 
including an opioid-based general anaesthesia with or without regional nerve block. 
 
3.1.1.1 Thoracic surgery 
Few studies have assessed the usefulness of gabapentin in reducing pain after 
thoracotomy. No evidence supports the role of gabapentin in a single dose of either 
600mg or 1200mg given 2h prior to surgery in reducing any of the three outcomes in 
the first 48h after surgery. However, when used in a single dose of 1200mg 1h 
preoperatively plus 600mg every 12h postoperatively for 48h, it may reduce pain, 
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opioid requirements and related side effects, resulting in an improvement in 
postoperative pulmonary function.19, 21, 22 
Gabapentin used in a single 2h preoperative dose of 600mg to 1200mg with or 
without another 1200mg daily for the first 48h postoperative appears to reduce both 
pain and opioid consumption after coronary artery bypass graft (CABG).8, 21 
 
3.1.1.2 Abdominal surgery 
Multiple reviews and meta-analyses have investigated the use of gabapentin in 
laparoscopic cholecystectomy. When given as a single dose of either 300mg or 600mg 
2h before surgery, gabapentin reduced postoperative pain and opioid needs in the first 
24h but the incidence of side effects was variable.6, 11, 19, 21 When multiple doses of 
1200mg 1h before surgery plus 400mg every 8h during the first 48h postoperative are 
employed, no difference in any of the outcomes was found.6, 18 
Regarding upper abdominal surgery, a single dose of gabapentin 600mg 2h 
preoperatively effectively reduced pain and opioid consumption in the first 24h 
postoperative.17, 21 
Concerning gabapentin’s use in lower abdominal surgery, a single dose of 
600mg given up to 1h prior to surgery seems to have no effect on none of the outcomes 
in the first 48h postoperative.8, 21 
In nephrectomy, both 600mg of gabapentin 2h before surgery or after incision 
resulted in lower pain and less opioid requirements in the first 24h postoperative.11, 19 
 
3.1.1.3 Gynaecological surgery 
Several studies evaluated the use of gabapentin in open hysterectomy with 
numerous dosing regimens exploited, ranging from 300mg to 1200mg in a single 
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preoperative dose (various administration time frames) and/or multiple postoperative 
administrations in up to five postoperative days. A significant reduction in pain scores 
was seen when gabapentin was given preoperatively only but additional gabapentin 
postoperatively did not significantly affect it. However, all regimens reported a 
reduction in opioid needs as well as in opioid-related side effects.7, 8, 17, 19, 21, 23 
Interestingly, 1200mg of gabapentin given 1h before hysterectomy seems to be more 
effective than a 0.3mg/Kg I.V. bolus plus 0.05mg/Kg/h infusion of ketamine in 
reducing both pain and opioid consumption in the first 24h after surgery.7, 17 
A single preoperative dose of 600mg was evaluated in caesarean delivery, which 
resulted in a reduction in pain scores in the first 48h postpartum but not in opioid 
requirements nor in opioid-related adverse events. This was not associated with 
neonatal adverse outcomes.5, 21 
 
3.1.1.4 Orthopaedic surgery 
Concerning arthroscopic shoulder surgery, 800mg given 2h preoperatively 
neither significantly reduced pain nor opioid needs in the first 48h after surgery.7, 18, 21 
Numerous reviews and meta-analyses focused on the use of gabapentin in spinal 
surgery, with multiple dosage regimens ranging from 300mg to 1200mg in a single dose 
2h before surgery to the same amount partitioned over the first 24h after surgery. The 
majority of the results attained indicated a reduction in all three outcomes lasting for the 
first 24h hours after surgery. Despite this, no agreement can be reached as to which dose 
is more effective.7, 19, 21, 24 
Regarding hip arthroplasty, 1200mg of gabapentin given 1h before surgery 
combined with a single I.V. bolus dose of 0.15mg/Kg of ketamine didn’t reduce pain 
nor opioid consumption at 24h postoperative.21, 25 
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Several reviews evaluated the role of gabapentin in knee surgery, either in a sole 
preoperative dose of 600-1200mg or combined with multiple doses in the first four days 
postoperatively. In neither regimen did gabapentin reduce postoperative pain but it did 
decrease opioid consumption and opioid-related side effects in both.7, 17, 19, 21 
Lastly, gabapentin didn’t significantly reduce neither pain nor opioid requests in 
the first 24h postoperatively when given as a single dose of 300mg 2h before lower limb 
surgery.8, 21 
 
3.1.2 Pregabalin 
 
Multiple reviews and meta-analyses evaluated the usefulness of oral pregabalin 
in reducing postoperative pain, opioid consumption and/or opioid-related side effects, 
using various therapeutic regimens, regardless of the type of surgical procedure. The 
main conclusion is that preoperative pregabalin significantly decreases all three 
outcomes at an expense of an increased patient sedation, dizziness and visual 
disturbances. As with gabapentin, the best analgesic dose is yet to be discovered but it 
seems to be accepted that doses inferior to 100mg/d have little effect.9, 12, 19, 26 
Similarly to gabapentin, in most studies, pregabalin is used as part of a balanced 
analgesic scheme including an opioid-based general anaesthesia with or without 
regional nerve block. 
 
3.1.2.1 Thoracic surgery 
With respect to CABG, a preoperative dose of 150mg of pregabalin given 1h 
before surgery plus 75mg twice a day for five postoperative days didn’t reduce any of 
the outcomes at 24h postoperative.7, 10, 14, 15 
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3.1.2.2 Abdominal surgery 
Various reviews and meta-analyses assessed the efficacy of pregabalin in the 
setting of laparoscopic cholecystectomy. Pregabalin was given in doses ranging from 
50mg to 300mg, 1h before surgery, with or without multiple doses postoperatively. 
Only a dosage of 150mg 1h preoperatively showed to be effective in reducing pain and 
opioid consumption at 24h postoperatively. Curiously, a higher dose of 300mg given 1h 
before showed no significant effect on none of the outcomes.6, 10, 12-15, 17, 25, 26 
Regarding laparoscopic bariatric surgery, 150mg of pregabalin given 2h before 
surgery significantly reduced all three outcomes in the first 24h after the procedure.6, 12-
15, 26 
In prostatectomy, 150mg of pregabalin given 2h before surgery reduced 
postoperative opioid needs. No data are available regarding pain.25, 26 
 
3.1.2.3 Gynaecological surgery 
Numerous reviews and meta-analyses focused on the usefulness of pregabalin in 
various doses 1h preoperatively, with or without postoperative administration, in the 
setting of laparoscopic hysterectomy. When given in doses lower than 300mg 1h before 
surgery, pregabalin didn’t significantly reduce none of the three outcomes at 24h 
postoperative. A dosage of 300mg significantly reduced opioid consumption only for 
24h after surgery.6, 7, 10, 12, 14, 15, 17, 18, 25, 26 
Concerning open hysterectomy, results regarding a dosage of 300mg 1h 
preoperatively were inconsistent, with some reviews reporting a reduction in pain and 
opioid requirements but not in opioid-related side effects, while others reported no 
significant effect in any of the three outcomes, in the first 24h postoperative.7, 10, 12-15, 26 
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3.1.2.4 Orthopaedic surgery 
Several reviews and meta-analyses have evaluated the role of pregabalin in spine 
surgery. Neither 150mg nor 300mg, given 1-2h before surgery, plus 150mg twice in the 
first postoperative day were effective in reducing postoperative pain but did decrease 
opioid consumption in up to 48h postoperative.7, 9, 10, 14, 15, 24, 26 
Concerning total hip arthroplasty, 300mg of pregabalin administered 1h before 
surgery resulted in a significant reduction of opioid needs, but neither pain nor opioid-
related adverse events were lessened in the first 24h postoperative.10, 12, 14, 15, 17, 26 
Multiple reviews and meta-analyses appraised the effect of pregabalin in knee 
surgery. Pregabalin in a dose of 300mg, given 1-2h before surgery, with or without a 
postoperative prescription, significantly decreased opioid consumption but not opioid-
related side effects in the first 48h post operatively. Results regarding postoperative pain 
were conflicting.9, 10, 13-15, 17, 26 
 
3.2 Tricyclic anti-depressants  
 
Tricyclic Antidepressants (TCAs) have been used effectively for years in the 
management of chronic pain, but their safety and efficacy for analgesia in the 
perioperative period is yet to be determined.27, 28 
It is known that TCAs, in addition to inhibiting serotonin and noradrenaline 
reuptake, increase supraspinal availability of noradrenaline (thought to enhance 
descending inhibitory bulbospinal control), activate endogenous µ and δ opioid 
receptors, block sodium and calcium channels and inhibit N-methyl-D-aspartate 
New Acute Pain Indications for Old Drugs 16 
receptors, among others.27, 28 These mechanisms may suppress central sensitization, an 
import feature in postoperative pain. 
TCAs have several safety problems which should be rigorously accessed 
concerning their use in the postoperative setting. These include increased perioperative 
bleeding, serotonin syndrome and potentially adverse drug interactions, among others.27, 
28 
Few studies have focused on the usage of specific TCAs and not enough results 
are available to differentiate them into surgical categories. Amitriptyline, a first-
generation TCA, failed to demonstrate analgesic efficacy in third molar extraction and 
following hip/knee arthroplasty when given preoperatively in multiple time frames and 
multiple doses ranging from 25mg to 75mg. However, in spine surgery, if administered 
2h before surgery, 25mg orally reduced pain intensity at 24 h after surgery.27, 28 
Desipramine, second-generation TCA, was also ineffective in a single dose trial 
involving patients undergoing a variety of different surgical procedures when a dose of 
50mg was given on the first postoperative day. In contrast to those results, when given 
in multiple time frames and multiple doses, ranging from 25mg to 75mg, desipramine 
decreased pain after third molar extraction.27, 28 
 
3.3 N-methyl-D-aspartate receptor antagonists 
 
Glutamate is a major CNS neurotransmitter of primary nociceptive afferent 
nerve fibres, activating N-methyl-D-aspartate (NMDA) receptors on pain transmission 
neurons, both in the spinal cord and in the brain, in response to noxious stimuli. 
Ketamine, a NMDA receptor antagonist, binds to the NMDA receptors on 
inhibitory GABAergic interneurons, blocking the glutamatergic inputs. In the brain, this 
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causes abnormal excitatory activity in the cortex, hippocampus, and limbic system and, 
ultimately, unconsciousness. In the spinal cord, it decreases arousal by blocking NMDA 
mediated nociceptive signals from peripheral afferent neurons. In summary, it exerts its 
effects by dissociating the CNS from outside stimuli, thus blocking pain sensation.7, 29 
Due to its ability to modulate pain centrally by acting on NMDA, opioid and 
monoaminergic receptors, limiting central sensitization, ketamine has been studied as an 
option in postoperative pain prevention and treatment.6, 7, 17 Moreover, ketamine has 
recently been shown to have some anti-inflammatory properties, leading to the 
speculation that these may also be responsible for its anti-hyperalgesic effects.7, 29 
Ketamine’s bioavailability after intramuscular, intranasal or oral administration 
is 93%, 25-50% and 17-20%, respectively, and it is highly diffusible through the blood-
brain barrier. It is metabolized in the liver by cytochrome P450, resulting in high plasma 
concentrations of its main metabolite, norketamine, which has one-third of the analgesic 
efficacy of the parent compound. Thus, the effective metabolic half-life is 2.5-3 h.6, 7, 29 
When used in high doses, ketamine induces several adverse effects. In the CNS 
it can cause irritability, confusion, hallucinations, dissociation, headaches, impaired 
memory, nightmares, diplopia, nausea, and dizziness.30, 31 Systemically, it increases the 
blood pressure and heart rate, due to indirect sympathomimetic effects, and may cause 
urinary tract symptoms, such as urge incontinence and detrusor overactivity, and 
hepatotoxicity.7, 30 However, the central respiratory drive depression is marginal and 
airway patency is extraordinarily preserved, with minimal depression of protective 
pharyngeal and laryngeal reflexes.7, 29 
Ketamine has been exploited in various regimens in the setting of postoperative 
pain management, either pre-, intra- and/or postoperatively and either in a single bolus, 
epidurally, in an intravenous (I.V.) infusion or mixed with opioids (most commonly 
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with morphine) via patient controlled analgesia (PCA). It has been used in sub-
anaesthetic doses, i.e. no more than 1.0mg/Kg, when given as a bolus I.V. and no 
greater than 1.2mg/Kg/h when given as an infusion (either I.V. or epidurally).7, 32 When 
prescribed via PCA, the best lockout interval (i.e. the minimum time between two 
boluses) was determined to be 8min33, whereas the morphine to ketamine ratio is 
variable. Numerous administration techniques have also been studied. Some researchers 
favour continuous I.V. infusion without an associated opioid, reasoning that ketamine 
mixed with morphine via PCA is less effective due to the former’s suboptimal 
pharmacokinetic and pharmacodynamic effects7 . Others perceive that the main role of 
ketamine is to treat patients where regional anaesthesia is not used, since regional 
techniques are already successful at decreasing postoperative pain.31 Most studies 
conclude that perioperative administration of sub-anaesthetic doses of ketamine has 
some effect, even if not significant, at the expense of an increased incidence of minor 
psychomimetic effects, like transient hallucinations and vivid dreams. These side effects 
were rare, short-termed and ceased when stopping the ketamine infusion or 
administering a benzodiazepine.7, 30-32, 34-38 
 
3.3.1 Thoracic surgery 
Multiple reviews and meta-analyses assessed the role of ketamine in 
thoracotomy and various techniques have been exploited. Both a preoperative single 
I.M. or epidural dose of 1mg/Kg significantly reduced opioid needs but not pain nor 
opioid-related side effects, albeit the pain reduction was greater when ketamine was 
used epidurally.29 When given via a continuous epidural infusion of 0.05mg/Kg/h, 
combined with local anaesthetic, for 48h after surgery, ketamine effectively reduced 
postoperative pain.7, 29 If administered via PCA containing 0.5mg to 1mg of morphine 
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plus 0.5mg to 5mg of ketamine per bolus, in the first 72h postoperative, it significantly 
reduced pain and opioid consumption. Results regarding side effects were mixed.7, 30, 31, 
33-36 
Regarding CABG, a single I.V. bolus of 0.075mg/Kg plus an infusion of 
0.075mg/Kg/h immediately after anaesthesia induction and prescribed for 48h after 
surgery reduced opioid consumption but not pain nor opioid-related side effects.7, 32 
 
3.3.2 Abdominal surgery 
When used in a sole bolus dose of 1mg/Kg at anaesthesia induction, ketamine 
reduced pain and opioid consumption in the first 24h after laparoscopic 
cholecystectomy.6 
Many reviews and meta-analyses have evaluated the usefulness of ketamine in 
upper abdominal surgery. If administered in a single bolus dose of 1mg/Kg at 
anaesthesia induction, it reduced both pain and opioid consumption in the first 24h after 
surgery. However, when prescribed in lower doses, ketamine decreases opioid needs but 
not postoperative pain.32 When given up to 48h after surgery in an intraoperative dose 
ranging from 0.3mg/Kg to 1mg/Kg combined with an I.V. infusion ranging from 
0.1mg/Kg/h to 0.5mg/Kg/h, it reduced pain and opioid requirements.32, 33 Lastly, if 
administered via PCA containing 0.4mg of morphine and 1mg of ketamine per bolus, in 
the first 24h postoperative, it significantly reduced all three outcomes.34, 36 
Concerning low abdominal surgery, a single bolus dose of a minimum of 
0.5mg/Kg, administered at anaesthesia induction, reduced postoperative pain and opioid 
requirements, but not opioid-related side effects, in the first 24h after surgery.5, 32 When 
the same bolus dose is combined with a 24h continuous I.V. or epidural infusion of 
0.25mg/Kg/h of ketamine, results were identical.7, 29, 30 Lower infusion rates reduced 
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opioid consumption only.32 Finally, PCA comprising 0.4mg of morphine and 1mg of 
ketamine per bolus in the first 24h postoperative significantly reduced all three 
outcomes.34, 36 
Regarding ketamine’s use in nephrectomy, a bolus dose of 0.5mg/Kg plus an 
I.V. infusion of 0.5mg/Kg/h for 48h postoperatively reduced both postoperative pain 
and opioid requests.29, 30, 32, 33, 36 Lower doses produced no effects.32 
With respect to prostatectomy, a 0.5mg/Kg bolus, administered either pre- or 
postoperatively, combined with a 0.12mg/Kg/h I.V. infusion for 48h after surgery 
reduced postoperative pain and opioid consumption.30, 32, 33, 36 Again, inferior doses 
produced no effects.29, 30, 32 
 
3.3.3 Gynaecological surgery 
Concerning laparoscopic gynaecological surgery, a preoperative dose of 
0.15mg/Kg reduced opioid consumption but not pain scores at 24h postoperatively.6, 32, 
38 
Multiple reviews and meta-analyses have assessed the effectiveness of ketamine 
in open hysterectomy, with many different techniques employed. When prescribed just 
before anaesthetic induction in a sole bolus dose of up to 0.4mg/Kg, it had no effect on 
any of the outcomes at 24h postoperatively.30, 32, 38 If given in a 0.3mg/Kg bolus plus 
0.05mg/Kg/h I.V. infusion, ketamine reduced opioid consumption but not pain in the 
first 24h after surgery. As mentioned above, this regimen seems to be less effective than 
1200mg of gabapentin given 1h before hysterectomy.7, 17, 32 Likewise, an infusion at a 
rate of 0.15mg/Kg/h I.V. for 48 hours postoperatively reduced opioid consumption but 
not pain.32, 36 Finally, PCA with 1mg of morphine plus up to 2mg of ketamine per bolus 
administered for 48h after surgery had no effect on any of the outcomes.33, 34, 36 
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In the setting of caesarean section, a bolus dose of up to 1.0mg/Kg at anaesthetic 
induction produced no significant effects on any of the outcomes.30, 36 On the contrary, a 
bolus of 0.5mg/Kg 10min after birth combined with an infusion of 0.12mg/Kg/h for 12h 
postoperatively reduced opioid consumption for 24h after surgery.30 Neither technique 
was associated with neonatal adverse outcomes.30, 36 
 
3.3.4 Orthopaedic surgery 
Several reviews and meta-analyses have assessed the role of ketamine in spine 
surgery and various techniques have been exploited. A bolus of 0.15mg/Kg at 
anaesthesia induction reduces pain and opioid needs at 24h after surgery.7, 32 When 
given in the preoperative period, bolus of 0.5mg/Kg to 1mg/Kg combined with a 24-48h 
intra- and/or postoperative infusion of up to 0.6mg/Kg/h I.V., ketamine significantly 
reduced opioid consumption. Results regarding postoperative pain were inconsistent.7, 
17, 30, 32, 33, 36 Lower doses seem to have no significant effect.32, 36 If administered at an 
infusion rate of 0.06mg/Kg/h I.V. intra- and postoperatively for 24h significantly 
reduced all three outcomes.30 Lastly, PCA with 1.5mg of morphine plus 1.5mg of 
ketamine per bolus prescribed for 48h after surgery had no effect on any of the 
outcomes.33, 36 
Regarding hip surgery, a bolus of 0.5mg/Kg plus an infusion of 0.12mg/Kg/h 
I.V. intra- and postoperatively for 24h reduced opioid requests but not pain scores.17, 32 
If administered via PCA with 1.5mg of morphine plus 1.5mg of ketamine per bolus, for 
48h postoperatively, it had no effect on any of the outcomes.33, 36 
Many reviews and meta-analyses have evaluated the usefulness of ketamine in 
knee surgery and various techniques have been used. A single bolus dose of 0.15mg/Kg 
at anaesthesia induction is effective in reducing opioid consumption for 48h 
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postoperative, but mixed results were attained about postoperative pain.7, 29, 32 When 
given as bolus 0.2mg/Kg to 0.5mg/Kg of combined with an infusion rate ranging from 
0.06mg/Kg/h to 0.18mg/Kg/h I.V. for 48h after surgery, ketamine significantly reduced 
opioid requirements. Again, different results were achieved regarding pain.7, 29, 32 If 
prescribed at an infusion rate of 0.36mg/Kg/h I.V. during surgery it reduced pain and 
opioid consumption for 24h postoperative.30 Finally, PCA with 1.5mg of morphine plus 
1.5mg of ketamine per bolus, administered for 48h after surgery, had no effect on any of 
the outcomes.33, 36 
 
4. Discussion 
 
When physicians ponder the hypothesis of non-opioid analgesic regimens to 
treat pain, several questions arise: Does the use of the adjuvant have a clinically relevant 
impact on morbi-mortality and pain intensity? Does it lead to a reduction in analgesics 
requirements, especially those associated with significant adverse events, for instance 
opioids? And does the chosen drug have a favourable profile concerning adverse 
effects?  
The effect of gabapentinoids and ketamine seems to be greater on opioid 
consumption than on postoperative pain. Throughout the different surgical categories 
described above, there was a more homogeneous reduction in opioid requirements 
(namely, in the majority of thoracic, abdominal and orthopaedic surgeries) than in pain 
scores (sporadically in some types of thoracic, abdominal and orthopaedic surgeries). 
This uneven reduction can be explained by variations in: anaesthetic protocols21, 30, 33 
(the use of general anaesthesia only or combined with regional anaesthesia, more 
effectively reducing pain); type and number of intraoperative drugs7, 21, 30, 33 (opioids, 
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NSAIDs, acetaminophen, benzodiazepines or various others); and PCA protocols.7, 34 
There may also be differences in hospital practices regarding: prescription by the 
attending doctors, drugs administration by the nursing staff and postoperative pain 
assessment and registering.7, 21, 32, 34 All these factors can influence the results. 
These drugs appear to be more effective in surgeries that involve peripheral 
nerve injury and thus cause neuropathic postoperative pain and require higher opioid 
usage. This finding is consistent with previous research, which has shown larger 
reductions in pain and in opioid requirements with higher pain scores.6, 9, 12, 21, 32, 36 
However, pain reduction may be big enough to reach statistical significance but not 
high enough to be clinically meaningful.10, 15 
Results are even more inconsistent regarding PONV, especially since not all 
papers analyse this outcome. The overall trend favours a reduction in PONV by both 
gabapentinoids and ketamine, although this is not a linear finding. Again, different 
protocols may influence this outcome: some use ondansetron, droperidol, 
dexamethasone, and other drugs as PONV prophylaxis,7 enhancing patient recovery. 
This makes it difficult to assess the real effect of gabapentinoids and ketamine on 
PONV. Furthermore, considering the abovementioned effect of these drugs in reducing 
opioid consumption, it is unknown how much of this reduction in PONV is due to the 
drugs themselves and not due to a reduction in opioids consumption.  
The use of gabapentinoids and ketamine was associated with minor side effects, 
namely sedation7, 10, 13, 21 and dizziness10, 26 and hallucinations,5, 31, 32 respectively, which 
were limited to a short period of time after surgery. Although uncommon and minor, 
they may be worrisome in the elderly.8, 10, 16, 37 The risk of these events must be weight 
against the individual benefit of a better pain treatment and a reduction in PONV and 
opioid consumption. 
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The best analgesic dose of each drug is yet to be discovered. However, effective 
gabapentin doses ranged from 300mg/d to 1200mg/d; pregabalin doses inferior to 
100mg/d had little effect; ketamine was always used in sub-anaesthetic doses, i.e. no 
more than 1.0mg/Kg when given as an I.V. bolus and no greater than 1.2mg/Kg/h when 
given as an infusion (either I.V. or epidurally).  
Regarding TCAs, the low number of studies available assessing their role in 
acute postoperative pain reduces their clinical significance. Moreover, since their 
analgesic efficacy becomes evident only after days to weeks of gradual dose titration in 
chronic pain settings, their role in acute postoperative pain might be of little importance, 
especially considering the associated bleeding risk and the potential for adverse drug 
interactions.27, 28  
The main limitation to this review was the heterogeneity among anaesthetic 
protocols, analgesic regimens (different type, number and dosage of drugs) and hospital 
practices (drugs prescription and administration and pain assessment and registering) in 
the evaluated studies. 
For these reasons, future studies should explore the analgesic and side effects of 
these drugs using similar protocols and populations, so that we can better understand 
their real role in acute postoperative pain management. Dose-response studies and cost-
efficacy analysis are also needed to determine the clinical effectiveness as well as the 
relative healthcare costs in clinical practice settings. 
 
5. Conclusion 
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The role of gabapentinoids TCAs and ketamine in postoperative pain 
management is not yet fully understood. They appear to reduce opioid consumption 
and, to a lower extent, pain scores.  
In this reviewer’s opinion, gabapentinoids and ketamine will have a role in acute 
postoperative pain management, especially in the most painful surgeries, in which nerve 
damage occurs requiring higher postoperative opioids. They will also play a part in 
patients who are at risk for severe postoperative pain and/or who have known history of 
severe opioid-related side effects. In contrast, TCAs don’t appear to have any clinical 
usefulness in acute postoperative pain management, but could be important in 
preventing the development of persistent postoperative pain. 
It is in these settings that future research should focus. 
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